The roles of antimicrobial peptides in innate host defense

Current Pharmaceutical Design

Volumn 15, Issue 21, 2009, Pages 2377-2392

  Diamond, Gill ^a   Beckloff, Nicholas ^a   Weinberg, Aaron ^b   Kisich, Kevin O ^c,d  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d IMC Inc   (United States)

Author keywords

Defensin; Innate immunity; Magainin; Membrane disruption

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; BETA DEFENSIN 1; BETA DEFENSIN 2; BETA DEFENSIN 3; CALCIUM ION; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR4; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17; NEUTROPHIL PROTEIN 1; POLYPEPTIDE ANTIBIOTIC AGENT; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL MEMBRANE; CALCIUM MOBILIZATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DNA IMMUNIZATION; ENZYME INHIBITION; GENE EXPRESSION; GENE INDUCTION; HOST RESISTANCE; HUMAN; HYDROPHOBICITY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM; LYMPHOMA; MEMBRANE BINDING; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; PHAGOCYTOSIS; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; SYNOVIUM; TUMOR IMMUNITY; VASCULARIZATION; VITAMIN D RESPONSIVE ELEMENT; WOUND HEALING;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; IMMUNITY, INNATE;

EID: 69249096200     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682325     Document Type: Review

References (246)

1. Brogden, KA. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
2. Diamond G, Laube D, Klein-Patel ME. In: Hancock REW, Devine DA, Eds. Mammalian Host Defence Peptides. UK: Cambridge University Press, Cambridge 2004; vol. 6: Pp. 111-38.
3. Hancock REW, Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 2000; 8: 402-10.
4. Kaiser V, Diamond G. Expression of mammalian defensin genes. J Leukoc Biol 2000; 68: 779-84.
5. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
7. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc Lond (Biol) 1922; 93: 306-17.
8. Skarks RC, Watson DW. Antimicrobial factors of normal tissues and fluids. Bacteriol Rev 1957; 21: 273-94.
9. Zeya HI, Spitznagel JK. Antibacterial and enzymic basic proteins from leukocyte lysosomes: Separation and identification. Science 1963; 142: 1085-87.
10. Hultmark D, Steiner H, Rasmuson T, Boman HG. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur J Biochem 1980; 106: 7-16.
11. Selsted ME, Brown DM, DeLange RJ, Lehrer RI. Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. J Biol Chem 1983; 258: 14485-9.
12. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987; 84: 5449-53.
13. Cole AM, Weis P, Diamond G. Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder. J Biol Chem 1997; 272: 12008-13.
14. Lemaitre B, Hoffmann J. The host defense of Drosophila melanogaster. Annu Rev Immunol 2007; 25: 697-743.
15. van Dijk A, Veldhuizen EJ, Haagsman HP. Avian defensins. Vet Immunol Immunopathol 2008.
16. Castro MS, Fontes W. Plant defense and antimicrobial peptides. Protein Pept Lett 2005; 12: 13-8.
17. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
18. Brahmachary M, Krishnan SP, Koh JL, Khan AM, Seah SH, Tan TW, et al. ANTIMIC: A database of antimicrobial sequences. Nucleic Acids Res 2004; 32: D586-9.
19. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-20.
20. Boman HG. Innate immunity and the normal microflora. Immunol Rev 2000; 173: 5-16.
21. Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, et al. Dermcidin: A novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001; 2: 1133-7.
22. Lai R, Liu H, Hui Lee W, Zhang Y. An anionic antimicrobial peptide from toad Bombina maxima. Biochem Biophys Res Commun 2002; 295: 796-9.
23. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981; 292: 246-8.
24. Fennell JF, Shipman WH, Cole LJ. Antibacterial action of melittin, a polypeptide from bee venom. Proc Soc Exp Biol Med 1968; 127: 707-10
25. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992; 73: 472-9.
26. Zanetti M, Gennaro R, Romeo D. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374: 1-5.
27. Zhu S. Evidence for myxobacterial origin of eukaryotic defensins. Immunogenetics 2007; 59: 949-54.
28. Wong JH, Xia L, Ng TB. A review of defensins of diverse origins. Curr Protein Pept Sci 2007; 8: 446-59.
29. Selsted ME. Theta-defensins: Cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci 2004; 5: 365-71.
30. Ganz T. Hepcidin - a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 2006; 306: 183-98.
31. Edgerton M, Koshlukova SE. Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva. Adv Dent Res 2000; 14: 16-21.
32. Gao G, Guo X, Goff SP. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 2002; 297: 1703-6.
33. Powers JP, Hancock RE. The relationship between peptide structure and antibacterial activity. Peptides 2003; 24: 1681-91.
34. Rozek A, Friedrich CL, Hancock RE. Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry 2000; 39: 15765-74.
35. Hoover DM, Chertov O, Lubkowski J. The structure of human beta-defensin-1: New insights into structural properties of beta-defensins. J Biol Chem 2001; 276: 39021-6.
36. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, et al. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 2000; 275: 32911-8.
37. Sawai MV, Jia HP, Liu L, Aseyev V, Wiencek JM, McCray PB, Jr., et al. The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry 2001; 40: 3810-6.
38. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: Mechanisms of membrane permeabilization. Science 1991; 251: 1481-5.
39. Tang YQ, Yuan J, Osapay G, Osapay K, Tran D, Miller CJ, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999; 286: 498-502
40. Tran D, Tran PA, Tang YQ, Yuan J, Cole T, Selsted ME. Homodimeric theta-defensins from rhesus macaque leukocytes: Isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J Biol Chem 2002; 277: 3079-84.
41. Yount NY, Yeaman MR. Multidimensional signatures in antimicrobial peptides. Proc Natl Acad Sci USA 2004; 101: 7363-8.
42. Zimmermann GR, Legault P, Selsted ME, Pardi A. Solution structure of bovine neutrophil β-defensin-12: The peptide fold of the β-defensins is identical to that of classical defensins. Biochemistry 1995; 34: 13663-71.
43. Xie C, Prahl A, Ericksen B, Wu Z, Zeng P, Li X, et al. Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids. J Biol Chem 2005; 280: 32921-9.
44. Wieprecht T, Dathe M, Krause E, Beyermann M, Maloy WL, MacDonald DL, et al. Modulation of membrane activity of amphipathic, antibacterial peptides by slight modifications of the hydrophobic moment. FEBS Lett 1997; 417: 135-40.
45. Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998; 102: 874-80.
46. Kluver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, Adermann K. Structure-activity relation of human beta-defensin 3: Influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005; 44: 9804-16.
47. Sawai MV, Waring AJ, Kearney WR, McCray PB, Jr., Forsyth WR, Lehrer RI, et al. Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides. Protein Eng 2002; 15: 225-32.
48. Szyk A, Wu Z, Tucker K, Yang D, Lu W, Lubkowski J. Crystal structures of human alpha-defensins HNP4, HD5, and HD6. Protein Sci 2006; 15: 2749-60.
49. Aerts AM, Francois IE, Cammue BP, Thevissen K. The mode of antifungal action of plant, insect and human defensins. Cell Mol Life Sci 2008.
50. Kuwano K, Tanaka N, Shimizu T, Kida Y. Antimicrobial activity of inducible human beta defensin-2 against Mycoplasma pneumoniae. Curr Microbiol 2006; 52: 435-8.
51. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6: 447-56.
52. Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60: 1068-74.
53. Salvatore M, Garcia-Sastre A, Ruchala P, Lehrer RI, Chang T, Klotman ME. alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 2007; 196: 835-43.
54. Ryan LK, Diamond G, Amrute S, Feng Z, Weinberg A, Fitzgerald-Bocarsly P. Detection of HBD1 peptide in peripheral blood mono-nuclear cell subpopulations by intracellular flow cytometry. Peptides 2003; 24: 1785-94.
55. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, et al. Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002; 99: 1813-8.
56. Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci USA 2000; 97: 8245-50.
57. Rice WG, Ganz T, Kinkade JMJ, Selsted ME, Lehrer RI, Parmley RT. Defensin-rich dense granules of human neutrophils. Blood 1987; 70: 757-65.
58. Ladokhin AS, Selsted ME, White SH. Sizing membrane pores in lipid vesicles by leakage of co-encapsulated markers: Pore formation by melittin. Biophys J 1997; 72: 1762-6.
59. Christensen B, Fink J, Merrifield RB, Mauzerall D. Channel-forming properties of cecropins and related model compounds incorporated into planar lipid membranes. Proc. Natl. Acad. Sci. (USA) 1988; 85: 5072-6.
60. Lee MT, Chen FY, Huang HW. Energetics of pore formation induced by membrane active peptides. Biochemistry 2004; 43: 3590-9.
61. Bechinger B, Aisenbrey C, Bertani P. The alignment, structure and dynamics of membrane-associated polypeptides by solid-state NMR spectroscopy. Biochim Biophys Acta 2004; 1666: 190-204.
62. Wu Y, He K, Ludtke SJ, Huang HW. X-ray diffraction study of lipid bilayer membranes interacting with amphiphilic helical peptides: diphytanoyl phosphatidylcholine with alamethicin at low concentrations. Biophys J 1995; 68: 2361-9.
63. Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 1998; 160: 91-6.
64. Kavanagh K, Dowd S. Histatins: Antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004; 56: 285-9.
65. Brotz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Mode of action of the lantibiotic mersacidin: Inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother 1995; 39: 714-9.
66. Agerberth B, Boman A, Andersson M, Jörnvall H, Mutt V, Boma HG. Isolation of three antibacterial peptides from pig intestine: Gastric inhibitory polypeptide(7-42), diazepam-binding inhibitor(32-86) and a novel factor, peptide 3910. Eur J Biochem 1993; 216: 623-9.
67. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 2007; 120: 13-22.
68. Scott MG, Yan H, Hancock RE. Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect Immun 1999; 67: 2005-9.
69. Weidenmaier C, Kristian SA, Peschel A. Bacterial resistance to antimicrobial host defenses - an emerging target for novel antiinfective strategies? Curr Drug Targets 2003; 4: 643-9.
70. Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1529-39.
71. Lourenzoni MR, Namba AM, Caseli L, Degreve L, Zaniquelli ME. Study of the interaction of human defensins with cell membrane models: relationships between structure and biological activity. J Phys Chem B 2007; 111: 11318-29.
72. Yau WM, Wimley WC, Gawrisch K, White SH. The preference of tryptophan for membrane interfaces. Biochemistry 1998; 37: 14713-8.
73. Chan DI, Prenner EJ, Vogel HJ. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochim Biophys Acta 2006; 1758: 1184-202.
74. Dennison SR, Morton LH, Harris F, Phoenix DA. Antimicrobial properties of a lipid interactive alpha-helical peptide VP1 against Staphylococcus aureus bacteria. Biophys Chem 2007; 129: 279-83.
75. Huang HW. Action of antimicrobial peptides: Two-state model. Biochemistry 2000; 39: 8347-52.
76. Chen HM, Leung KW, Thakur NN, Tan A, Jack RW. Distinguishing between different pathways of bilayer disruption by the related antimicrobial peptides cecropin B, B1 and B3. Eur J Biochem 2003; 270: 911-20.
77. Lee MT, Hung WC, Chen FY, Huang HW. Mechanism and kinetics of pore formation in membranes by water-soluble amphipathic peptides. Proc Natl Acad Sci USA 2008; 105: 5087-92.
78. Lee DG, Park Y, Jin I, Hahm KS, Lee HH, Moon YH, et al. Structure-antiviral activity relationships of cecropin A-magainin 2 hybrid peptide and its analogues. J Pept Sci 2004; 10: 298-303.
79. Matsuzaki K, Murase O, Fujii N, Miyajima K. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore. Biochemistry 1995; 34: 6521-6.
80. Matsuzaki K, Murase O, Miyajima K. Kinetics of pore formation by an antimicrobial peptide, magainin 2, in phospholipid bilayers. Biochemistry 1995; 34: 12553-9.
81. Yang L, Harroun TA, Weiss TM, Ding L, Huang HW. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001; 81: 1475-85.
82. Spaar A, Munster C, Salditt T. Conformation of peptides in lipid membranes studied by x-ray grazing incidence scattering. Biophys J 2004; 87: 396-407.
83. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996; 35: 11361-8
84. Matsuzaki K, Sugishita K, Harada M, Fujii N, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta 1997; 1327: 119-30.
85. Matsuzaki K, Sugishita K, Ishibe N, Ueha M, Nakata S, Miyajima K, et al. Relationship of membrane curvature to the formation of pores by magainin 2. Biochemistry 1998; 37: 11856-63.
86. Chen Y, Guarnieri MT, Vasil AI, Vasil ML, Mant CT, Hodges RS. Role of peptide hydrophobicity in the mechanism of action of alpha helical antimicrobial peptides. Antimicrob Agents Chemother 2007; 51: 1398-406.
87. Lugtenberg B, Van Alphen L. Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. Biochim Biophys Acta 1983; 737: 51-115.
88. Dorschner RA, Lopez-Garcia B, Peschel A, Kraus D, Morikawa K, Nizet V, et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. Faseb J 2006; 20: 35-42.
89. Pazgier M, Li X, Lu W, Lubkowski J. Human defensins: Synthesis and structural properties. Curr Pharm Des 2007; 13: 3096-118.
90. Steinberg DA, Hurst MA, Fujii CA, Kung AH, Ho JF, Cheng FC, et al. Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother 1997; 41: 1738-42.
91. Devine DA, Marsh PD, Percival RS, Rangarajan M, Curtis MA. Modulation of antibacterial peptide activity by products of Porphyromonas gingivalis and Prevotella spp. Microbiology 1999; 145 (Pt 4): 965-71.
92. Sieprawska-Lupa M, Mydel P, Krawczyk K, Wojcik K, Puklo M, Lupa B, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004; 48: 4673-9.
93. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006; 4: 529-36
94. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 1999; 35: 45-53.
95. Mosca DA, Hurst MA, So W, Viajar BS, Fujii CA, Falla TJ. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother 2000; 44: 1803-8.
96. Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 2006; 273: 251-6.
97. Shelburne CE, Coulter WA, Olguin D, Lantz MS, Lopatin DE. Induction of beta-defensin resistance in the oral anaerobe Porphyromonas gingivalis. Antimicrob Agents Chemother 2005; 49: 183-7.
98. Laube DM, Yim S, Ryan LK, Kisich KO, Diamond G. Antimicrobial peptides in the airway. Curr Top Microbiol Immunol 2006; 306: 153-82.
99. O'Neil DA. Regulation of expression of beta-defensins: Endogenous enteric peptide antibiotics. Mol Immunol 2003; 40: 445-50.
100. Selsted M.E., Szlarek D, Lehrer RI. Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. Infect. Immun 1984; 45: 150-4.
101. Caverly JM, Diamond G, Gallup JM, Brogden KA, Dixon RA, Ackermann MR. Coordinated expression of tracheal antimicrobial peptide and inflammatory-response elements in the lungs of neonatal calves with acute bacterial pneumonia. Infect Immun 2003; 71: 2950-5.
102. Russell JP, Diamond G, Tarver AP, Scanlin TF, Bevins CL. Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha. Infect. Immun 1996; 64: 1565-8.
103. Brahmachary M, Schonbach C, Yang L, Huang E, Tan SL, Chowdhary R, et al. Computational promoter analysis of mouse, rat and human antimicrobial peptide-coding genes. BMC Bioinformatics 2006; 7(Suppl 5): S8.
104. Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. Curr Opin Hematol 1997; 4: 53-8.
105. Ouellette AJ, Selsted ME. Paneth cell defensins: Endogenous peptide components of intestinal host defense. FASEB J 1996; 10: 1280-9.
106. Date Y, Nakazato M, Shiomi K, Toshimori H, Kangawa K, Matsuo H, et al. Localization of human neutrophil peptide (HNP) and its messenger RNA in neutrophil series. Ann Hematol 1994; 69: 73-7.
107. Harwig SSL, Park ASK, Lehrer RI. Characterization of defensin precursors in mature human neutrophils. Blood 1992; 79: 1532-7.
108. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 2002; 3: 583-90.
109. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, YS L-B, Stratman JL, et al. Regulation of Intestinal alpha-Defensin Activation by the Metalloproteinase Matrilysin in Innate Host Defense. Science 1999; 286: 113-7.
110. Beckloff N, Diamond G. Computational analysis suggests beta-defensins are processed to mature peptides by signal peptidase. Protein Peptide Lett 2008; 15: 536-40.
111. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol 2004; 173: 3482-91.
112. Kanda N, Watanabe S. IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes. Eur J Immunol 2008; 38(5): 1287-96.
113. Legarda D, Klein-Patel ME, Yim S, Yuk MH, Diamond G. Suppression of NF-kappaB-mediated beta-defensin gene expression in the mammalian airway by the Bordetella type III secretion system. Cell Microbiol 2005; 7: 489-97.
114. Kao CY, Kim C, Huang F, Wu R. Requirements for two proximal NF-kappa B binding sites and Ikappa B-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway Epithelium. J Biol Chem 2008; 283(22): 15309-18.
115. Chung WO, Dommisch H, Yin L, Dale BA. Expression of defensins in gingiva and their role in periodontal health and disease. Curr Pharm Des 2007; 13: 3073-83.
116. Krisanaprakornkit S, Kimball JR, Dale BA. Regulation of human beta-defensin-2 in gingival epithelial cells: The involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family. J Immunol 2002; 168: 316-24.
117. Chung WO, Dale BA. Innate immune response of oral and foreskin keratinocytes: Utilization of different signaling pathways by various bacterial species. Infect Immun 2004; 72: 352-8.
118. Chung WO, Dale BA. Differential utilization of nuclear factor-kappaB signaling pathways for gingival epithelial cell responses to oral commensal and pathogenic bacteria. Oral Microbiol Immunol 2008; 23: 119-26.
119. Duits LA, Ravensbergen B, Rademaker M, Hiemstra PS, Nibbering PH. Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002; 106: 517-25.
120. Armogida SA, Yannaras NM, Melton AL, Srivastava MD. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 2004; 25: 297-304.
121. Kuhn L, Trabattoni D, Kankasa C, Semrau K, Kasonde P, Lissoni F, et al. Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr 2005; 39: 138-42.
122. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/ hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95: 9541-6.
123. Agerberth B, Grunewald J, Castanos VE, Olsson B, H J, Wigzell H, et al. Antibacterial Components in Bronchoalveolar Lavage Fluid from Healthy Individuals and Sarcoidosis Patients. Am J Respir Crit Care Med 1999; 160: 283-90.
124. Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999; 103: 1113-7.
125. Engelhardt JF, Yankaskas JR, Wilson JM. In vivo retroviral gene transfer into human bronchial epithelia of xenografts. J Clin Invest 1992; 90: 2598-607.
126. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-60.
127. Hosokawa I, Hosokawa Y, Komatsuzawa H, Goncalves RB, Karimbux N, Napimoga MH, et al. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin Exp Immunol 2006; 146: 218-25.
128. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-12
129. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003; 88: 695-705.
130. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005; 19: 1067-77.
131. Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction Of Cathelicidin In Normal And Cf Bronchial Epithelial Cells By 1,25-Dihydroxyvitamin D3. J. Cystic Fibrosis 2007; 6: 403-10.
132. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-3.
133. Elloumi HZ, Holland SM. Complex regulation of human cathelicidin gene expression: Novel splice variants and 5′UTR negative regulatory element. Mol Immunol 2008; 45: 204-17.
134. Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pita O, Leung DY, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179: 984-92.
135. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341-8.
136. Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O, Vogelmeier C, et al. Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 2004; 173: 1219-23.
137. Tapper H. The secretion of preformed granules by macrophages and neutrophils. J Leukoc Biol 1996; 59: 613-22.
138. Jan MS, Huang YH, Shieh B, Teng RH, Yan YP, Lee YT, et al. CC chemokines induce neutrophils to chemotaxis, degranulation, and alpha-defensin release. J Acquir Immune Defic Syndr 2006; 41: 6-16.
139. Zheng Y, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br J Dermatol 2007; 157: 1124-31.
140. Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002; 70: 4591-9.
141. Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, et al. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 2006; 177: 1864-71.
142. Diamond DL, Kimball JR, Krisanaprakornkit S, Ganz T, Dale BA. Detection of beta-defensins secreted by human oral epithelial cells. J Immunol Methods 2001; 256: 65-76.
143. Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006; 12: 636-41.
144. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Ganz T. Human β-defensin-1: An antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101: 1633-42.
145. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, et al. Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998; 95: 14961-6.
146. Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg 2008; 27: 144-50.
147. Kisich KO, Howell MD, Boguniewicz M, Heizer HR, Watson NU, Leung DY. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J Invest Dermatol 2007; 127: 2368-80.
148. Kisich KO, Carspecken CW, Fieve S, Boguniewicz M, Leung DY. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol 2008; 122(1): 62-8.
149. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
150. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-9.
151. Yuk MH, Harvill ET, Cotter PA, Miller JF. Modulation of host immune responses, induction of apoptosis and inhibition of NF-kappaB activation by the Bordetella type III secretion system. Mol Microbiol 2000; 35: 991-1004.
152. Angot A, Vergunst A, Genin S, Peeters N. Exploitation of eukaryotic ubiquitin signaling pathways by effectors translocated by bacterial type III and type IV secretion systems. PLoS Pathog 2007; 3: E3.
153. Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, et al. Downregulation of bactericidal peptides in enteric infections: A novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001; 7: 180-5.
154. Bergman P, Johansson L, Asp V, Plant L, Gudmundsson GH, Jonsson AB, et al. Neisseria gonorrhoeae downregulates expression of the human antimicrobial peptide LL-37. Cell Microbiol 2005; 7: 1009-17.
155. Al-Haddawi M, Mitchell GB, Clark ME, Wood RD, Caswell JL. Impairment of innate immune responses of airway epithelium by infection with bovine viral diarrhea virus. Vet Immunol Immunopathol 2007; 116: 153-62.
156. Contreras A, Umeda M, Chen C, Bakker I, Morrison JL, Slots J. Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. J Periodontol 1999; 70: 478-84.
157. Yokota S, Okabayashi T, Yokosawa N, Fujii N. Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20. FASEB J 2008; 22: 74-83.
158. Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005; 125: 738-45
159. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086-93.
160. Klein-Patel ME, Diamond G, Boniotto M, Saad S, Ryan LK. Inhibition of beta-Defensin Gene Expression in Airway Epithelial Cells by Low Doses of Residual Oil Fly Ash is Mediated by Vanadium. Toxicol Sci 2006; 92: 115-25.
161. Duits LA, Rademaker M, Ravensbergen B, van Sterkenburg MA, van Strijen E, Hiemstra PS, et al. Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids. Biochem Biophys Res Commun 2001; 280: 522-5.
162. Jang BC, Lim KJ, Suh MH, Park JG, Suh SI. Dexamethasone suppresses interleukin-1beta-induced human beta-defensin 2 mRNA expression: involvement of p38 MAPK, JNK, MKP-1, and NF-kappaB transcriptional factor in A549 cells. FEMS Immunol Med Microbiol 2007; 51: 171-84.
163. Laube D, Dongari-Bagtzoglou A, Kashleva H, Eskdale J, Gallagher G, Diamond G. Differential regulation of innate immune response genes in gingival epithelial cells stimulated with Aggregatibacter actinomycetemcomitans. J Periodontal Res 2008; 43: 116-23.
164. Carlsson G, Wahlin YB, Johansson A, Olsson A, Eriksson T, Claesson R, et al. Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia. J Periodontol 2006; 77: 744-51.
165. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study. Lancet 2002; 360: 1144-9.
166. de Haar, SF Hiemstra PS, van Steenbergen MT, Everts V, Beertsen W. Role of polymorphonuclear leukocyte-derived serine proteinases in defense against Actinobacillus actinomycetemcomitans. Infect Immun 2006; 74: 5284-91.
167. Matsushita I, Hasegawa K, Nakata K, Yasuda K, Tokunaga K, Keicho N. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002; 291: 17-22.
168. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: High-throughput SNP assays and association with candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol 2003; 41: 90-6.
169. Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S. A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. Aids 2004; 18: 1598-600.
170. Milanese M, Segat L, Pontillo A, Arraes LC, de Lima Filho JL, Crovella S. DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children. Aids 2006; 20: 1673-5.
171. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989; 84: 2017-20
172. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25: 465-72.
173. Nagaoka I, Hirota S, Niyonsaba F, Hirata M, Adachi Y, Tamura H, et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001; 167: 3329-38.
174. Scott MG, Vreugdenhil AC, Buurman WA, Hancock RE, Gold MR. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000; 164: 549-53.
175. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169: 3883-91.
176. Hoshino K, Ogawa K, Hishitani T, Kitazawa R. Influence of heart surgery on magnesium concentrations in pediatric patients. Pediatr Int 2003; 45: 39-44.
177. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000; 68: 9-14.
178. Chertov O, Michiel DF, Xu L, Wang M, Tani K, Murphy WJ, et al. Identification of defensin-1, defensin-2 and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996; 271: 2935-40.
179. Yang D, Chen Q, Schmidt AM, Anderson GM, Wang JM, Wooters J, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069-74.
180. Yang D, Chertov O, Oppenheim JJ. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: Receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 2001; 69: 691-7.
181. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004; 172: 4987-94.
182. Nagaoka I, Tamura H, Hirata M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006; 176: 3044-52.
183. Zuyderduyn S, Ninaber DK, Hiemstra PS, Rabe KF. The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. J Allergy Clin Immunol 2006; 117: 1328-35.
184. Yu J, Mookherjee N, Wee K, Bowdish DM, Pistolic J, Li Y, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007; 179: 7684-91.
185. Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I. Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002; 14: 421-6.
186. Chen X, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, et al. Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J Dermatol Sci 2006; 43: 63-6.
187. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 2001; 31: 1066-75.
188. Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Identification and Biological Characterization of Mouse beta-defensin 14, the orthologue of human beta-defensin 3. J Biol Chem 2008; 283: 5414-9.
189. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. Beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525-8.
190. Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, et al. Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol 2007; 37: 434-44.
191. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004; 111: 273-81.
192. Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci USA 2003; 100: 8880-5.
193. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting edge: Human beta defensin 3 - a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177: 782-6.
194. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. Aids 2003; 17: F39-48.
195. Van Wetering S, Mannesse-Lazeroms SP, Van Sterkenburg MA, Daha MR, Dijkman JH, Hiemstra PS. Effect of defensins on interleukin 8 synthesis in airway epithelial cells. Am J Physiol 1997; 272: L888-96.
196. Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594-604.
197. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N, et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003; 171: 6690-6.
198. Kang T, Yi J, Guo A, Wang X, Overall CM, Jiang W, et al. Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem 2001; 276: 21960-8.
199. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: Identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation. Blood 1993; 82: 3183-91.
200. Carretero M, Escamez MJ, Garcia M, Duarte B, Holguin A, Retamosa L, et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 2008; 128: 223-36.
201. Tarnawski A, Szabo IL, Husain SS, Soreghan B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J Physiol Paris 2001; 95: 337-44.
202. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005; 175: 4662-8.
203. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N. Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003; 170: 5583-9.
204. Aarbiou J, Ertmann M, van Wetering S, van Noort P, Rook D, Rabe KF, et al. Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J Leukoc Biol 2002; 72: 167-74.
205. Aarbiou J, Verhoosel RM, Van Wetering S, De Boer WI, Van Krieken JH, Litvinov SV, et al. Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Respir Cell Mol Biol 2004; 30: 193-201.
206. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379-89.
207. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, et al. An angiogenic role for the human peptide antibiotic LL-37/ hCAP-18. J Clin Invest 2003; 111: 1665-72.
208. Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol 2002; 198: 369-77.
209. Varoga D, Pufe T, Harder J, Schroder JM, Mentlein R, Meyer-Hoffert U, et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum 2005; 52: 1736-45.
210. Lillard JW, Jr., Boyaka PN, Chertov O, Oppenheim JJ, McGhee JR. Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 1999; 96: 651-6.
211. Brogden KA, Heidari M, Sacco RE, Palmquist D, Guthmiller JM, Johnson GK, et al. Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol Immunol 2003; 18: 95-9.
212. Tani K, Murphy WJ, Chertov O, Salcedo R, Koh CY, Utsunomiya I, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000; 12: 691-700.
213. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, et al. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104: 18631-5.
214. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167: 6644-53.
215. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
216. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-72.
217. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 2000; 92: 1228-39.
218. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med 1998; 188: 1075-82.
219. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-9.
220. Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146-56.
221. van Wetering S, Sterk PJ, Rabe KF, Hiemstra PS. Defensins: Key players or bystanders in infection, injury, and repair in the lung? J Allergy Clin Immunol 1999; 104: 1131-8.
222. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 1997; 158: 4129-36.
223. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404: 407-11.
224. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999; 11: 81-8.
225. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
226. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta 2008; Epub ahead of print.
227. Scott RW, Degrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol 2008.
228. Diamond G, Beckloff N, Ryan LK. Host defense peptides in the oral cavity and the lung: Similarities and differences. J Dent Res 2008; 87: 915-27.
229. Zasloff M, Martin B, Chen H-C. Antimicrobial Activity of Synthetic magainin Peptides and Several Analogues. Proc Natl Acad Sci 1988; 85: 910-3.
230. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human alpha-defensins. Antimicrob Agents Chemother 2005; 49: 269-75.
231. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998; 42: 2206-14.
232. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta-defensin 3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-13.
233. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68: 2748-55.
234. Ji S, Hyun J, Park E, Lee BL, Kim KK, Choi Y. Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J Periodontal Res 2007; 42: 410-9.
235. Joly S, Maze C, McCray PB, Jr., Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 2004; 42: 1024-9.
236. Wei GX, Campagna AN, Bobek LA. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Chemother 2006; 57: 1100-9.
237. Ji S, Kim Y, Min BM, Han SH, Choi Y. Innate immune responses of gingival epithelial cells to nonperiodontopathic and periodontopathic bacteria. J Periodontal Res 2007; 42: 503-10.
238. Varkey J, Nagaraj R. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob Agents Chemother 2005; 49: 4561-6.
239. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, et al. Identification of a novel, multifunctional beta-defensin (human beta- defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-64.
240. Huang LC, Jean D, Proske RJ, Reins RY, McDermott AM. Ocular surface expression and in vitro activity of antimicrobial peptides. Curr Eye Res 2007; 32: 595-609.
241. Midorikawa K, Ouhara K, Komatsuzawa H, Kawai T, Yamada S, Fujiwara T, et al. Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun 2003; 71: 3730-9.
242. Giacometti A, Cirioni O, Del Prete MS, Paggi AM, D'Errico MM, Scalise G. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Peptides 2000; 21: 1155-60.
243. Lundy FT, Nelson J, Lockhart D, Greer B, Harriott P, Marley JJ. Antimicrobial activity of truncated alpha-defensin (human neutrophil peptide (HNP)-1) analogues without disulphide bridges. Mol Immunol 2008; 45: 190-3.
244. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {beta}-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-96.
245. Feng Z, Jiang B, Chandra J, Ghannoum M, Nelson S, Weinberg A. Human beta-defensins: Differential activity against candidal species and regulation by Candida albicans. J Dent Res 2005; 84: 445-50.
246. Helmerhorst EJ, Van't Hof W, Veerman EC, Simoons-Smit I, Nieuw Amerongen AV. Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem J 1997; 326 (Pt 1): 39-45.